Management of multiple myeloma during COVID-19 pandemic Review
| Authors: | Jethava, Y. S.; Fonseca, R.; Landgren, O. |
| Review Title: | Management of multiple myeloma during COVID-19 pandemic |
| Abstract: | At the end of 2019, a novel coronavirus was identified as the cause of pneumonia cases in Wuhan, a city in the Hubei Province of China. On January 30, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international concern and, in March 2020, began to characterize it as a pandemic. The virus that causes COVID-19 is designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) In February 2020, the World Health Organization designated the disease COVID-19, which stands for coronavirus disease 2019. © 2020 |
| Keywords: | cancer recurrence; disease classification; pathophysiology; multiple myeloma; autologous stem cell transplantation; high risk patient; patient care; interleukin 6; world health organization; social distance; pandemic; human; priority journal; article; severe acute respiratory syndrome coronavirus 2; coronavirus disease 2019; case fatality rate |
| Journal Title: | Leukemia Research Reports |
| Volume: | 14 |
| ISSN: | 2213-0489 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-01-01 |
| Start Page: | 100212 |
| Language: | English |
| DOI: | 10.1016/j.lrr.2020.100212 |
| PROVIDER: | scopus |
| PMCID: | PMC7293439 |
| PUBMED: | 32704473 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 August 2020 -- Source: Scopus |
